Headlands Research, a clinical trial site network with locations across the U.S. and Canada, is launching its newest site on the U.S.-Mexico border in El Paso, Texas.

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE) and outlining plans to start a second pivotal trial.

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Wave Life Sciences has met its goal in a Duchenne muscular dystrophy (DMD) study, positioning it to talk to regulators about accelerated approval while continuing to track patients through to the completion of the trial.

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop protein therapeutics across multiple indications.

The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach of its clot-busting hardware.

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after receiving encouraging phase 2 data in lung and eye cancers, respectively.

After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is expected to extend the biotech’s cash runway into the second half of 2026.

Context Therapeutics is building up its bank of bispecific antibody candidates. The Philadelphia-based company is paying $11 million upfront for a T-cell engaging antibody from BioAtla, according to a Sept. 23 SEC filing.

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.